{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Brazil Medical Devices news", "home_page_url": "https://sharemaestro.com/newsreel/br/healthcare/medical-devices/", "feed_url": "https://sharemaestro.com/newsreel/br/healthcare/medical-devices/feed.json", "description": "Latest Medical Devices company headlines from Brazil, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:84980dbc017c4e1caacf816c96701866d11ab80a0313de34674c2e716016b3b7", "url": "https://finance.yahoo.com/markets/stocks/articles/strykers-q2-recovery-guidance-support-174900018.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/strykers-q2-recovery-guidance-support-174900018.html", "title": "Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half?", "content_text": "Stryker Corporation SYK entered the second half of 2026 with momentum restored after the March cybersecurity disruption. Second-quarter sales, earnings and margins improved as production recovered, while management narrowed its full-year outlook. The next test is execution. Stryker must keep normalizing production, convert elevated backlog into shipments and support a broad product launch cycle. Those factors will determine whether the stronger second half embedded in management's expectations materializes. Stryker's Q2 Recovery Rebuilt Momentum Stryker reported second-quarter net sales of $6.", "date_published": "2026-08-13T17:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "S1YK34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "S1YK34", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/208e7f4d-65bf-4ddb-99d6-157334a14169/"}]}}, {"id": "source:5971b49dee342142efd77297a630f9275b5f8928066a404b0980f77284728a39", "url": "https://finance.yahoo.com/markets/stocks/articles/stryker-13-6-3-months-174900364.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/stryker-13-6-3-months-174900364.html", "title": "Stryker Up 13.6% in 3 Months as Recovery Gains Strength, What's Next?", "content_text": "Stryker Corporation SYK shares have risen 13.6% in the past three months, outpacing the Zacks Medical sector's 12.9% gain and the S&P 500's 1.7% advance. The move has coincided with a sharper operating recovery after a difficult first quarter. The investor question is whether improving sales, margins and production can keep supporting the stock, or whether execution demands and a richer relative valuation now make the next leg higher harder to achieve.Zacks Investment Research Image Source: Zacks Investment Research Why Stryker's Three-Month Rally Has Support Stryker's second-quarter results g", "date_published": "2026-08-13T17:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "S1YK34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "S1YK34", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/208e7f4d-65bf-4ddb-99d6-157334a14169/"}]}}, {"id": "source:0cfcde4cddab96709ddbfbea14351e5e47db7dc607b47c80b30ee36a5f942748", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-bulls-look-optimistic-133003681.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-bulls-look-optimistic-133003681.html", "title": "Wall Street Bulls Look Optimistic About Medtronic (MDT): Should You Buy?", "content_text": "The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Medtronic (MDT). Medtronic currently has an average brokerage recommendation (ABR) of 1.90, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated", "date_published": "2026-08-13T13:30:03+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:6bebd5c6d2f8662a74ba8d37058c7efaf4228f2893397c2e5001d65410bc2a61", "url": "https://finance.yahoo.com/markets/stocks/articles/edwards-climbs-14-3-months-125100456.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/edwards-climbs-14-3-months-125100456.html", "title": "Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation", "content_text": "Edwards Lifesciences Corporation EW shares have gained 14% in the past three months as growth across its structural-heart franchises has strengthened the operating case. Second-quarter results showed double-digit expansion in transcatheter aortic valve replacement and faster growth in transcatheter mitral and tricuspid therapies. The rally leaves investors balancing broader growth and raised 2026 expectations against a valuation that already reflects meaningful execution. EW's 3-Month Gain Meets a Premium Valuation EW trades at 28.8X forward 12-month EPS, above 27.3X for the Zacks sub-industry", "date_published": "2026-08-13T12:51:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "E1WL34", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "E1WL34", "name": "Edwards Lifesciences Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/e03db612-2d5a-4b57-b1aa-2c90a6753007/"}, {"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:44eba28bf78d020546e41c688eb9802fde66248b39f513d8609af0d73f4e7a33", "url": "https://finance.yahoo.com/healthcare/articles/whats-backing-abbotts-established-pharmaceuticals-124900457.html", "external_url": "https://finance.yahoo.com/healthcare/articles/whats-backing-abbotts-established-pharmaceuticals-124900457.html", "title": "What's Backing Abbott's Established Pharmaceuticals Division Growth", "content_text": "Abbott Laboratories' ABT Established Pharmaceuticals Division (\"EPD\") continues to be a solid growth contributor, supported by its broad portfolio of branded generic medicines and strong commercial presence across emerging markets. In the second quarter of 2026, EPD sales increased 8.4% on a reported basis and 8.7% on a comparable basis. Key Emerging Markets delivered 10.7% comparable sales growth, driven by double-digit growth in several countries across Latin America and Asia Pacific. The strong performance highlights the benefits of EPD's diversified geographic footprint and its ability to ", "date_published": "2026-08-13T12:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABTT34", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABTT34", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/54923738-62b8-4347-824e-abcfed853bbd/"}, {"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:377de25772740c4444894cc2e57c9a08c195fe57135370fa67dc64a63d10f303", "url": "https://finance.yahoo.com/markets/stocks/articles/fitlife-brands-inc-ftlf-beats-124002204.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/fitlife-brands-inc-ftlf-beats-124002204.html", "title": "FitLife Brands Inc. (FTLF) Beats Q2 Earnings and Revenue Estimates", "content_text": "FitLife Brands Inc. (FTLF) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +11.11%. A quarter ago, it was expected that this company would post earnings of $0.14 per share when it actually produced earnings of $0.17, delivering a surprise of +21.43%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. FitLife Brands , which belongs t", "date_published": "2026-08-13T12:40:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:e62631285d7721245ec3e28a17d057d0d95d03a031f7951167d433420fe5c569", "url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-downgrades-stryker-upgrades-123705436.html", "external_url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-downgrades-stryker-upgrades-123705436.html", "title": "Wolfe Research downgrades Stryker, upgrades Abbott in med-tech shuffle", "content_text": "Investing.com -- Wolfe Research made two rating changes across large-cap medical devices, downgrading Stryker while upgrading Abbott Laboratories on Thursday. Analyst Mike Polark cut Stryker to Peer Perform, citing a demanding second-half setup following the company's March cyber disruption. He said the June quarter \"wasn't a huge catch up thus year not yet de-risked,\" leaving \"a higher-than-normal burden on 2H to deliver.\" As a result, Wolfe sees the near-term skew to estimates \"leans negative,\" with growth \"more likely to slow to 8% vs speed up to 10% in 2027.\" The firm flagged that Stryker'", "date_published": "2026-08-13T12:37:05+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "S1YK34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "S1YK34", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/208e7f4d-65bf-4ddb-99d6-157334a14169/"}]}}, {"id": "source:5bfbaac008af8b9a25871bd6e53ba01f7df0e4fef16c22372fcf01342a7379ff", "url": "https://finance.yahoo.com/markets/stocks/articles/heres-much-youd-invested-1000-123002482.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/heres-much-youd-invested-1000-123002482.html", "title": "Here's How Much You'd Have If You Invested $1000 in DexCom a Decade Ago", "content_text": "For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries. The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks. What if you'd invested in DexCom (DXCM) ten years ago? It may not have been easy to hold on to DXCM for all that time, but if you did, how much would your investment be worth today? DexCom's Business In-Depth With that in mind, let's take a look", "date_published": "2026-08-13T12:30:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "D1EX34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "D1EX34", "name": "DexCom, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b2c00c38-8c26-4d9c-a6aa-ac60da580f5e/"}]}}, {"id": "source:1e0cde33e45bc82a30375dfc4c94e9b07cb308ddf22aac26c5b00ca8d2be89dd", "url": "https://finance.yahoo.com/m/157854b1-0d26-3fa0-a565-352a2ee3928c/revisiting-former-stock-picks.html", "external_url": "https://finance.yahoo.com/m/157854b1-0d26-3fa0-a565-352a2ee3928c/revisiting-former-stock-picks.html", "title": "Revisiting Former Stock Picks Medtronic, Quantas Services, Lennar", "content_text": "Reassessing stock picks is one of the best habits an investor can build. Watch Doug discuss recent stock picks, provide input on the current market environment\u2014and take your questions. The daily chart illustrates how well the stock has performed relative to its peers on the ratio chart against the over the past two months. Continue Reading", "date_published": "2026-08-13T04:43:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:514e128ebb8254b2e7833258dba6fdd75fb5811bfb18edc60a79a42420c9a8e5", "url": "https://finance.yahoo.com/markets/stocks/articles/livanova-livn-could-5-undervalued-220952454.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/livanova-livn-could-5-undervalued-220952454.html", "title": "LivaNova (LIVN) Could Be 5% Undervalued Following Raised 2026 Guidance", "content_text": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. LivaNova (LIVN) raised its full year 2026 revenue and earnings guidance after reporting record quarterly revenue and significantly higher profitability, supported by demand for its Essenz heart-lung machine and a new supply agreement with Thermo Fisher Scientific. See our latest analysis for LivaNova. LivaNova's recent guidance lift comes after a strong run in the share price, with a 90 day share price return of 12.71% and a", "date_published": "2026-08-12T22:09:52+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "L2IV34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "L2IV34", "name": "LivaNova PLC", "sentiment_url": "https://sharemaestro.com/sentiment/84d1f394-8b68-4160-9a7e-cf42fab863a4/"}]}}, {"id": "source:7835a6b4b376fa6f740670085bc029bc18c05ead14857e55d06d331eda00396f", "url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-stock-worth-buying-growth-183600592.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-stock-worth-buying-growth-183600592.html", "title": "Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches?", "content_text": "DexCom, Inc. DXCM is entering the second half of 2026 with healthier margins, broader reimbursement and a larger continuous glucose monitoring opportunity. The investment question is whether that improving setup is enough to justify a premium valuation. Growth catalysts remain visible across U.S. coverage, product upgrades and international expansion. Yet competition, litigation and a forward earnings multiple above key benchmarks leave less room for execution misses. DXCM's Growth Case Is Still Broadening DexCom's addressable market is widening beyond intensive insulin users. All four of the ", "date_published": "2026-08-12T18:36:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABTT34", "D1EX34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABTT34", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/54923738-62b8-4347-824e-abcfed853bbd/"}, {"symbol": "D1EX34", "name": "DexCom, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b2c00c38-8c26-4d9c-a6aa-ac60da580f5e/"}]}}, {"id": "source:cb1fb61e2d7b4c9de7e8f3ba544e3579767d3406ea22a6d11486614a7eb1e9aa", "url": "https://finance.yahoo.com/healthcare/articles/dxcm-stock-nearly-35-ytd-183400790.html", "external_url": "https://finance.yahoo.com/healthcare/articles/dxcm-stock-nearly-35-ytd-183400790.html", "title": "DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026?", "content_text": "DexCom DXCM stock has rebounded sharply in 2026, gaining 34.8% after falling 14.7% in 2025, as investors increasingly recognize the company's improving growth profile and expanding continuous glucose monitoring (CGM) opportunity. The company's share price performance so far this year has outperformed the industry's 6.9% decline and S&P 500 Index's 13.1% gain. The second-quarter performance reflected recovery, with revenues rising 13% year over year and organic growth reaching 12%. U.S. revenues increased 11%, while international revenues jumped 19%, reflecting broader reimbursement, market-sha", "date_published": "2026-08-12T18:34:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABTT34", "D1EX34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABTT34", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/54923738-62b8-4347-824e-abcfed853bbd/"}, {"symbol": "D1EX34", "name": "DexCom, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b2c00c38-8c26-4d9c-a6aa-ac60da580f5e/"}]}}, {"id": "source:e2e53014098505128ba9b042fa06f1f76e2cbe50dbb782d539fd1cf552748935", "url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-rallies-52-5-3-183300640.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-rallies-52-5-3-183300640.html", "title": "DXCM Rallies 52.5% in 3 Months. Can the Stock Keep Climbing From Here?", "content_text": "DexCom, Inc. DXCM shares have climbed 52.5% in the past three months, a sharp re-rating that raises the standard for further gains. The next leg depends less on momentum alone and more on whether earnings growth, margin expansion and new-market access can keep pace with higher expectations. Recent results support the fundamental case, but the stock's premium valuation leaves less room for disappointment. Investors now have to weigh improving execution against competition and litigation risk. DXCM's 52.5% Rally Outpaces Key Benchmarks DXCM's three-month gain easily exceeds the 18.3% rise for th", "date_published": "2026-08-12T18:33:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABTT34", "D1EX34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABTT34", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/54923738-62b8-4347-824e-abcfed853bbd/"}, {"symbol": "D1EX34", "name": "DexCom, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b2c00c38-8c26-4d9c-a6aa-ac60da580f5e/"}]}}, {"id": "source:0f3f921f4e754d1dc87f0170b5d5e6487b23b1075953275044ad300b7bd58823", "url": "https://finance.yahoo.com/healthcare/articles/dexcoms-raised-2026-outlook-sustain-183300821.html", "external_url": "https://finance.yahoo.com/healthcare/articles/dexcoms-raised-2026-outlook-sustain-183300821.html", "title": "Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum?", "content_text": "DexCom, Inc. DXCM raised its 2026 revenue and margin outlook after a stronger second quarter, shifting more attention toward profitability. The question is whether better gross margin and operating leverage can persist as organic growth improves. The guidance increase is encouraging, but foreign exchange, manufacturing investment and product-transition costs still matter. Sustaining the margin step-up will require continued execution across products, geographies and channels. DexCom's Q2 Results Reset the 2026 Baseline DexCom reported second-quarter 2026 revenues of $1.31 billion, up 13.1% yea", "date_published": "2026-08-12T18:33:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABTT34", "D1EX34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABTT34", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/54923738-62b8-4347-824e-abcfed853bbd/"}, {"symbol": "D1EX34", "name": "DexCom, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b2c00c38-8c26-4d9c-a6aa-ac60da580f5e/"}]}}, {"id": "source:3ea6e701ff7683fcac8c3f9bcb8cf44f16546528c61754b8293901a2b441debc", "url": "https://finance.yahoo.com/markets/commodities/articles/latest-global-whey-protein-market-173000212.html", "external_url": "https://finance.yahoo.com/markets/commodities/articles/latest-global-whey-protein-market-173000212.html", "title": "[Latest] Global Whey Protein Market Size/Share Worth USD 26.04 Billion by 2034 at a 7.56% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)", "content_text": "Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Whey Protein Market size & share revenue was valued at approximately USD 12.58 Billion in 2024 and is expected to reach USD 13.52 Billion in 2025 and is expected to reach around USD 26.04 Billion by 2034, at a CAGR of 7.56% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Abbott, Alpavit, Arla Foods, Carbery Group, Davisco Foods International, Inc., Fonterra Co-operative Group Ltd., Glanbia plc, Hilmar Cheese Company, Inc., LACTALIS Ingredients, Leprino Foods Company, Maple Island, Inc., Milk Specialties, Milkaut SA, Nestle S.A., Nutricia (Danone), Olam International, Sanofi S.A., Saputo Inc., Wheyco GmbH and others. Austin, TX, USA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled \"Whey Protein Market Size, Trends and Insights By Type (Whey Protein Isolates (WPI), Whey Protein Concentrates (WPC), Whey Protein Hydrolysates (WPH)), By Application (Sports Nutrition, Dietary Supplements, Infant Formula, Food Additives, Beverages, Feed), By End Users (Athletes, Bodybuilders, Lifestyle Users), By Distribution Channel (Supermarkets/Hypermarkets, Convenience Stores, Specialty Stores, Online Stores), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 \u2013 2034\" in its research database. \"According to the latest research study, the demand of global Whey Protein Market size & share was valued at approximately USD 12.58 Billion in 2024 and is expected to reach USD 13.52 Billion in 2025 and is expected to reach a value of around USD 26.04 Billion by 2034, at a compound annual growth rate (CAGR) of about 7.56% during the forecast period 2025 to 2034.\" Click Here to Access a Free Sample Report of the Global Whey Protein Market @ https://www.custommarketinsights.com/request-for-free-sample/?reportid=72482 Overview According to industry experts at CMI, the implementation of new strategies and technologies by manufacturers presents lucrative opportunities for players in the Whey Protein Market during the forecast period. Furthermore, the growing significance of organized retailing is expected to drive the future growth of the market. Request a Customized Copy of the Whey Protein Market Report @https://www.custommarketinsights.com/request-for-customization/?reportid=72482 Key Trends & Drivers Story Continues Clean-Label and Natural Products: There is a growing demand for clean-label whey protein products as consumers are now demanding more transparency in their supplements and to use more natural ingredients. A big indicator of this trend is the preference for products made without artificial ingredients, colors, or preservatives. Organic whey protein and non-GMO products are most popular in the premium products. The brands are also seeking to attract the consumers who want transparency regarding ethical sourcing and traceability. The clean-label trend supports the trend for healthier eating and sustainability, prompting manufacturers to have clearer labelling practices and reformulate products to meet consumers' desires for authentic and pure supplements. Growth of Ready-to-Drink (RTD) Beverages: Convenience-based living has allowed demand for ready-to-drink whey protein to rise. More consumers prefer portable and on-the-go options that supply an adequate level of protein without preparation. RTD shakes and drinks that provide protein fortification have quickly become commonplace for athletic consumers, busy working individuals, and lifestyle consumers. Flavourings, texture, variety, active ingredients (less sugar), etc. are innovating at exciting rates to make beverages more attractive to consumers from a wider range of market segments. The beverages may also be more/less expensive, but the premium packaging and singl", "date_published": "2026-08-12T17:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABTT34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABTT34", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/54923738-62b8-4347-824e-abcfed853bbd/"}]}}, {"id": "source:2100e637b2916ecb584e6b354b330a6f85d10b7b8fa369baf89de13620dc54c4", "url": "https://finance.yahoo.com/markets/stocks/articles/two-years-growth-barely-change-172001135.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/two-years-growth-barely-change-172001135.html", "title": "Two Years Of Growth Barely Change What You Pay For Intuitive Surgical", "content_text": "Photo by 127071 on Pixabay Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years. Intuitive Surgical (ISRG) trades at about $401.23, roughly 32% below its 52-week high and down about 15% over the past twelve months while the S&P 500 returned 22%. A fall that size usually leaves a stock cheap. This one still costs about 37.7 times its last twelve months of adjusted earnings, and what happens to that number by 2027 turns on a price the company has not set. Where The Multiple Actually Lands In 2027 Ana", "date_published": "2026-08-12T17:20:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:9078eeff64895395d45ce68b34ef3420beeaaf767b2ec54c1c0b7464effb3fd7", "url": "https://finance.yahoo.com/healthcare/articles/livanova-livn-q2-2026-earnings-153440720.html", "external_url": "https://finance.yahoo.com/healthcare/articles/livanova-livn-q2-2026-earnings-153440720.html", "title": "LivaNova (LIVN) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Briana Gotlin Chief Executive Officer and member of the Board of Directors - Vladimir Makatsaria Chief Innovation Officer - Ahmet Tezel Chief Financial Officer - Alex Shvartsburg Need a quote from a Motley Fool analyst? Email pr@fool.com Full Conference Call Transcript Operator: Good day, ladies and gentlemen, and welcome to the LivaNova PLC Second Quarter 2026 Earnings Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would n", "date_published": "2026-08-12T15:34:40+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "L2IV34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "L2IV34", "name": "LivaNova PLC", "sentiment_url": "https://sharemaestro.com/sentiment/84d1f394-8b68-4160-9a7e-cf42fab863a4/"}]}}, {"id": "source:236f34736a111bb242258345d7e1c88edda917f48b269c364f2bb5538f36f2f3", "url": "https://finance.yahoo.com/healthcare/articles/abbott-big-ten-bring-back-131400198.html", "external_url": "https://finance.yahoo.com/healthcare/articles/abbott-big-ten-bring-back-131400198.html", "title": "Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis", "content_text": "\"We Give Blood\" brings together all 18 Big Ten\u00ae schools in a competition to drive the most blood donations and win $1 million from global healthcare company Abbott For only the second time in its history, the American Red Cross has declared a national blood crisis after donations dropped to a four-year summer low, threatening the availability of lifesaving blood for patients across the country Abbott and the Big Ten urge people to donate blood now and will count those early donations toward the competition, which officially kicks off Aug. 26 Anyone can donate blood anywhere in the U.S. between", "date_published": "2026-08-12T13:14:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABTT34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABTT34", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/54923738-62b8-4347-824e-abcfed853bbd/"}]}}, {"id": "source:93a8437a003e42bdc1cec61e325e382b08164d5e79e56bcc2ecbd8cc4c72cb21", "url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-sees-500-intuitive-surgical-122519688.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-sees-500-intuitive-surgical-122519688.html", "title": "Oppenheimer Sees $500 for Intuitive Surgical as Rivals Stall", "content_text": "This article first appeared on GuruFocus. Intuitive Surgical (NASDAQ:ISRG) rose 0.90% premarket after Oppenheimer upgraded the robotic surgery company to Outperform from Perform with a $500 price target. The firm's case rests less on Intuitive than on its competitors: workflow integration problems for Johnson & Johnson's (NYSE:JNJ) Ottava system and physical footprint constraints for Medtronic's (NYSE:MDT) Hugo, potentially leaving the da Vinci franchise without a credible domestic challenger in the near term. Oppenheimer also pointed to the Per Click Model as a way into lower-acuity ambulator", "date_published": "2026-08-12T12:25:19+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:725cdc2008db873d64e658c758bcf4ed9e80627c38054193be9f41278642f761", "url": "https://www.nasdaq.com/articles/biotech-stocks-52-week-highs-almr-30-q2-reports-dyn-cgem-dxcm-cah", "external_url": "https://www.nasdaq.com/articles/biotech-stocks-52-week-highs-almr-30-q2-reports-dyn-cgem-dxcm-cah", "title": "Biotech Stocks At 52-Week Highs - ALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH", "content_text": "(RTTNews) - The following biotech stocks reached a 52-week high on August 11, 2026, driven up by key catalysts such as positive quarterly or full year reports. Alamar Biosciences Inc. (ALMR) Alamar Biosciences is a proteomics company that has develops a liquid biopsy platform alongside instruments and services for the early detection of diseases. Following a rise of over 30%, the company hit a 52-week high of $38.54 on Tuesday. On Monday, the company stated that net losses in the second quarter widened to $13.19 million, compared to $7.02 million in the previous year. Total revenue surged to $", "date_published": "2026-08-12T07:45:56+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "D1EX34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "D1EX34", "name": "DexCom, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b2c00c38-8c26-4d9c-a6aa-ac60da580f5e/"}]}}, {"id": "source:578a0f2db601796dd5dbafacfdc29748269b258cca81fd8d2fed95ac1f7dea2e", "url": "https://finance.yahoo.com/healthcare/articles/does-medtronic-mdt-still-trade-023547555.html", "external_url": "https://finance.yahoo.com/healthcare/articles/does-medtronic-mdt-still-trade-023547555.html", "title": "Does Medtronic (MDT) Still Trade At A Discount After Its CE Mark Win?", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Medtronic stock has delivered a 20.8% gain over the past three years, yet current checks suggest it now sits close to its estimated intrinsic value rather than at a clear discount. At the same time, earnings-based multiples still screen the shares as undervalued, which sets up a debate over how much upside is left from here. A 20.8% return over three years points to steady value creation for Medtronic shareholders, not a rapid rerating. Progress in highe", "date_published": "2026-08-12T02:35:47+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:640f91104b792f847e01800e8eb1613daed98a78b72905c44aa08b953c433f86", "url": "https://finance.yahoo.com/healthcare/articles/stryker-syk-comeback-quarter-looks-212323255.html", "external_url": "https://finance.yahoo.com/healthcare/articles/stryker-syk-comeback-quarter-looks-212323255.html", "title": "Stryker\u2019s (SYK) Comeback Quarter Looks Great, But At What Cost?", "content_text": "Stryker (NYSE:SYK) turned in one of its stronger quarters in recent memory on July 30, with sales climbing 9.4% to $6.6 billion and reported EPS jumping 44.1% to $3.30. The numbers arrive as the company works its way back from a cyber incident that had rattled its business, and CEO Kevin Lobo pointed to that recovery as proof of the company's resilience. But a closer look at how those earnings were adjusted tells a more complicated story about what is really driving the bottom line.Stryker's (SYK) Comeback Quarter Looks Great, But At What Cost? Bull Case: Growth That Touched Every Corner Of Th", "date_published": "2026-08-11T21:23:23+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "S1YK34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "S1YK34", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/208e7f4d-65bf-4ddb-99d6-157334a14169/"}]}}, {"id": "source:7cd8b308fd1ba8ee1d12f8541454ba69d33a2e88a8e29e6993906d377fa06a13", "url": "https://finance.yahoo.com/markets/stocks/articles/top-research-reports-meta-texas-203100631.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/top-research-reports-meta-texas-203100631.html", "title": "Top Research Reports for Meta, Texas Instruments & CrowdStrike", "content_text": "Tuesday, August 11, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Texas Instruments Inc. (TXN) and CrowdStrike Holdings, Inc. (CRWD), as well as a micro-cap stock Weyco Group, Inc. (WEYS). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country. These research reports have been hand-picked from the roughly 70 reports published by our analyst team t", "date_published": "2026-08-11T20:31:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:87f3f3c3d7a52b0e838831f823951d5707a7816c1b703a90b5d58c54f9f329f6", "url": "https://finance.yahoo.com/markets/stocks/articles/medtronic-mdt-wins-analyst-upgrades-191512624.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/medtronic-mdt-wins-analyst-upgrades-191512624.html", "title": "Medtronic (MDT) Wins Analyst Upgrades, Is It Fully Priced?", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Medtronic (MDT) has moved back into focus after multiple analyst upgrades tied to what they describe as the company's strongest annual revenue growth in a decade, supported by its cardiac portfolio and new product launches. See our latest analysis for Medtronic. Over the past quarter Medtronic has picked up momentum, with a 90 day share price return of 16.39% and a 30 day gain of 6.61%, while the 1 year total shareholder return is close to flat and the 5", "date_published": "2026-08-11T19:15:12+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:a93731d0c9c40eb23dcb21e7d72b4b1b03117182e350815ead3bff07ebac932a", "url": "https://finance.yahoo.com/video/arrow-exploration-confirms-four-zones-174110053.html", "external_url": "https://finance.yahoo.com/video/arrow-exploration-confirms-four-zones-174110053.html", "title": "Arrow Exploration confirms four zones at Icaco 3, opens up ~10 new drilling locations", "content_text": "Arrow Exploration Corp (TSX-V:AXL, AIM:AXL, OTC:CSTPF) CEO Marshall Abbott tells Proactive's Stephen Gunnion that the Icaco 3 well has confirmed up to four hydrocarbon-bearing zones in the Icaco extension of the Tapir Block in Colombia, opening almost 10 additional development locations across the Ubaque, Guadalupe and Carbonera C7 intervals. The IC-HZ4 and IC-HZ5 horizontal wells encountered a record Ubaque thickness of over 100 feet, containing 13.7 API crude, with Abbott saying the Ubaque trend extends across the northern part of the Tapir Block, supporting further development drilling. With five new water disposal cellars complete, Arrow is preparing to skid its rig and drill continuously until at least June next year. Abbott said production currently sits above 5,000 boe/d, with the programme expected to push output \"well north\" of that level. The company remains cash-flow positive above its capex spend, and Abbott said the current oil price environment supports a more aggressive drilling stance. On the Tapir Block licence extension, Abbott said he recently met Colombia's national regulator and Ecopetrol in Bogota, pointing to Arrow's track record of five discoveries, 40 development wells and $127 million invested as evidence it's the type of explorer authorities want. He described dialogue as \"very positive,\" with a decision expected before year-end. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #ArrowExploration #AXL #oilexploration #crudeoil #Colombia #TapirBlock #Icaco #Ecopetrol #energystocks #resourceinvesting View Comments", "date_published": "2026-08-11T17:41:10+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABTT34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABTT34", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/54923738-62b8-4347-824e-abcfed853bbd/"}]}}, {"id": "source:1669df33eaba3e6eee9714c010f314c05d1e8287e8ce389932ee77aaead1dfe1", "url": "https://finance.yahoo.com/markets/stocks/articles/number-one-reason-keep-buying-130939372.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/number-one-reason-keep-buying-130939372.html", "title": "The Number One Reason I Keep Buying Intuitive Surgical Now For The Long Run", "content_text": "Quick Read ISRG is down 31% YTD, but its razor-and-razorblade model now delivers 85% recurring revenue across a fleet of 11,710 da Vinci systems. MDT's Hugo and JNJ's Ottava remain early or pre-commercial, leaving ISRG's $1.73 billion quarterly instruments-and-accessories stream with no real soft-tissue competition. The dV5 supercycle is early, with only 1,700 of nearly 13,000 total systems upgraded and over 100 platform updates still planned. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Intuitive Surgical didn't make the cut. Grab the names FREE today. ", "date_published": "2026-08-11T13:09:39+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:9b0747406a31f261a432fba0c0e5eb1aba2c71244b46ea5c19d6bb0ddefce0e0", "url": "https://finance.yahoo.com/healthcare/articles/abbott-google-launch-first-kind-130000853.html", "external_url": "https://finance.yahoo.com/healthcare/articles/abbott-google-launch-first-kind-130000853.html", "title": "Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI", "content_text": "Multi-year collaboration combines ongoing glucose insights from Abbott's Lingo biowearable with Google Health's technology to create a more comprehensive view of personal health Partnership includes a large-scale research study to better inform artificial intelligence (AI) coaching available in the Google Health app and future Lingo product features Lingo, Abbott's over-the-counter continuous glucose monitor (CGM), helps people understand the impact of nutrition, activity, sleep and stress on their glucose so they can make meaningful lifestyle changes ABBOTT PARK, Ill., Aug. 11, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a first-of-its-kind partnership with Google Health to redefine how people understand and manage their health. By combining glucose insights from Abbott's Lingo biowearable with Google's expertise in artificial intelligence (AI) and consumer technology, the multi-year collaboration makes personalized metabolic insights more actionable, helping people take a more proactive approach to their health. The collaboration is designed to bring metabolic health insights into people's daily routines through a seamless, AI-powered experience. Through the Google Health app, Lingo users will be able to view glucose trends alongside other health and wellness metrics in a unified experience, helping them better understand how daily behaviors influence their overall well-being. Google's Health Coach will use these insights to deliver personalized, contextual recommendations designed to help users build sustainable habits related to nutrition, activity, sleep and recovery. The partnership will focus on three areas: Connecting glucose data to a more complete picture of health: Integrating ongoing glucose insights from the Lingo continuous glucose monitor (CGM) into Google Health to help users understand their body's response to daily habits and make better lifestyle and nutrition choices in the moment. Delivering AI-powered, personalized health guidance: Combining glucose insights with Google Health Coach to provide tailored recommendations that help people build healthier habits. Establishing new science about metabolic health: Conducting one of the largest real-world metabolic health studies to date, integrating continuous glucose, wearable, laboratory, and survey data to uncover connections between activity, sleep, wellbeing, and metabolic health, informing more personalized guidance that supports healthier day-to-day decisions. Rates of metabolic health challenges continue to rise globally. Prediabetes, one of the fastest-growing health crises in the U.S., impacts over 115 million American adults with more than 2 in 5 adults affected and approximately 8 in 10 are completely unaware they have it.[1] Additionally, poor metabolic health can lead to other chronic conditions such as Type 2 diabetes, cardiovascular disease and certain cancers.[2] The partnership between Abbott and Google Health aims to help people better understand the connection between their daily habits and overall well-being, empowering earlier and more informed action to help slow the development and progression of conditions related to poor metabolic health. Story Continues \"The biggest challenge in healthcare isn't treating disease\u2014it's helping people stay healthier longer,\" said Olivier Ropars, divisional vice president of Abbott's Lingo business. \"Abbott's leadership in biowearables and Google's expertise in AI and consumer technology create a powerful opportunity to make personalized insights available at unprecedented scale. Additionally, we are advancing metabolic health research through one of the largest real-world studies of its kind, generating new insights into the relationship between glucose and everyday behaviors. That research will help shape future AI-powered guidance and metabolic health innovation. Together, we can help people better understand their bodies and take action before health challenges become health conditions.\" Lin", "date_published": "2026-08-11T13:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABTT34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABTT34", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/54923738-62b8-4347-824e-abcfed853bbd/"}]}}, {"id": "source:a7cc9f369a9e2ed3cd16858a5d3b642a5276c8871db9133dde26f3c04ec07faa", "url": "https://finance.yahoo.com/healthcare/articles/versa-vascular-appoints-bill-shields-120000282.html", "external_url": "https://finance.yahoo.com/healthcare/articles/versa-vascular-appoints-bill-shields-120000282.html", "title": "Versa Vascular Appoints Bill Shields as Chief Executive Officer", "content_text": "Company Expands Series C Financing to $42M SANTA CRUZ, Calif., August 11, 2026--(BUSINESS WIRE)--Versa Vascular, Inc., a pioneering medical device company dedicated to transforming tricuspid valve disease treatment, announced the appointment of Bill Shields as Chief Executive Officer. Former Versa CEO David Hovda is retiring and will remain an advisor to the company. Shields spent the last 15 years with Medtronic's structural heart franchise, most recently as Vice President and General Manager of its Transcatheter Mitral and Tricuspid Therapies division, where he spent seven years leading prod", "date_published": "2026-08-11T12:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:1e0e00363db074638cbc860140fc49273515a220d295b2895102a2c88136eada", "url": "https://finance.yahoo.com/healthcare/articles/pulsed-field-ablation-global-market-090500258.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pulsed-field-ablation-global-market-090500258.html", "title": "Pulsed Field Ablation Global Market Report 2026 Now Available - Profiles Boston Scientific, Medtronic, Biosense Webster, and 15 Other Players", "content_text": "Company Logo Pulsed Field Ablation MarketPulsed Field Ablation Market Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The \"Pulsed Field Ablation Market by Therapeutic Area, Product Components, Application Area, Source of Ablation, Key Geographical Regions, and Sales Forecast of Leading Players - Trends and Forecast till 2035\" has been added to ResearchAndMarkets.com's offering. The global pulsed field ablation market is projected to expand from approximately USD 3.2 billion in 2026 to USD 14.6 billion by 2035, representing a compound annual growth rate of 18.4% during the forecast period. Rising atr", "date_published": "2026-08-11T09:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "MDTC34", "B1SX34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}, {"symbol": "B1SX34", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/2490ca3f-bb1e-4ec5-a10a-2731c88f683b/"}]}}, {"id": "source:1c8e1137cbdd39b6aea8b289794d24a367c007eba5a577b44e7c22e467624381", "url": "https://finance.yahoo.com/healthcare/articles/abbott-vs-medtronic-consistent-growth-224625108.html", "external_url": "https://finance.yahoo.com/healthcare/articles/abbott-vs-medtronic-consistent-growth-224625108.html", "title": "Abbott vs. Medtronic: Is Consistent Growth Better Than a Turnaround Story?", "content_text": "Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) are both prominent names in the Medtech space. Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Medtronic (NYSE:MDT), meanwhile, continued to build on its turnaround, reporting its strongest annual revenue growth in a decade as several high-growth platforms gained momentum. So, which is the more compelling long-term investment opportunity: Abbott's (NYSE:ABT) consistent execution or Medtronic's (NYSE:MDT) improving growth trajectory?Spectral AI (MDAI) Secures $17.7 Million to Launch Burn Wound AI System A patient viewing their medical diagnosis on a digital healthcare ecosystem. Bull Case Abbott's (NYSE:ABT) second-quarter results reinforced one of the company's biggest competitive advantages: its ability to generate growth from multiple businesses simultaneously. While investors often focus on its medical device portfolio, diagnostics emerged as one of the strongest contributors during the quarter. Sales in its diagnostics segment rose 42% to $3.09 billion in fiscal Q2, surpassing the estimate \u200bof $3.02 billion, emerging as one of the company's strongest performers during the quarter. Its cancer \u2060diagnostics business, which was recently integrated through the Exact Sciences buyout, is benefiting from an expanding base that comprises both new and repeat users of the colorectal cancer screening test, Cologuard. Furthermore, Abbott Laboratories (NYSE:ABT) reaffirmed its full-year 2026 comparable sales growth guidance of 6.5% to 7.5%, suggesting confidence in its operations. The company also raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to the previous range of $5.38 to $5.58. While Abbott's (NYSE:ABT) investment case centers on diversification and consistent execution, Medtronic's (NYSE:MDT) appeal increasingly lies in whether its long-awaited turnaround is finally taking hold. One of the most prominent factors supporting Medtronic's (NYSE:MDT) turnaround story is the company's reporting of its highest annual revenue growth in 10 years in its fiscal Q4 and full-year 2026 results. Q4 revenue reached $9.8 billion, up 9.9% as reported and 6.6% organic, and FY 26 revenue was $36.4 billion, adjusted revenue of $36.3 billion, up 8.4% as reported and 5.8% organic. Those results suggest Medtronic's (NYSE:MDT) recovery is becoming increasingly broad-based rather than relying on a single product cycle, an important distinction for investors evaluating whether the turnaround is sustainable, especially in its highest growth opportunities such as Affera, Symplicity, Hugo, Altaviva, and Stealth AXiS. Story Continues Beyond the headline numbers, Medtronic's (NYSE:MDT) newer growth platforms are continually gaining traction. Symplicity Spyral for hypertension is now annualizing at approximately $100 million in revenue, while products such as Hugo and Affera continue expanding the company's exposure to faster-growing MedTech markets. BTIG also recently argued that improving sentiment across the broader MedTech sector could provide an additional tailwind if utilization trends remain healthy. Bear Case Abbott's (NYSE:ABT) second-quarter results were undoubtedly strong, but the company's full-year outlook still relies on a stronger second half. While management raised its adjusted EPS guidance, it reaffirmed rather than increased its comparable sales growth outlook of 6.5% to 7.5%, suggesting that it remains measured on the pace of revenue growth. The company is also counting on several pipeline products to contribute more meaningfully in the second half of 2026 and into fiscal 2027. If those launches ramp more slowly than expected, the acceleration implied by management's outlook could prove more difficult to achieve. Similarly", "date_published": "2026-08-10T22:46:25+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABTT34", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABTT34", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/54923738-62b8-4347-824e-abcfed853bbd/"}, {"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:99a501eedeb3958ebe6a4d1351adb2e9a43c8bc2f34e87f9aa19ae7d64103286", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-medtronic-healthcare-223657921.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-medtronic-healthcare-223657921.html", "title": "Johnson & Johnson vs. Medtronic: Which Healthcare Stock Is Better Positioned After Earnings?", "content_text": "Johnson & Johnson (NYSE:JNJ) delivered another strong quarter in fiscal Q2 2026, with reported sales increasing 6.6% year over year to $25.31 billion and surpassing analysts' average estimate of around $25.05 billion. Adjusted earnings per share reached $2.90, also exceeding estimates of $2.85. The healthcare giant raised its full-year outlook and said it remains on track to generate more than $100 billion in annual revenue for the first time in its 140-year history. Medtronic (NYSE:MDT), meanwhile, ended fiscal 2026 with its fastest annual revenue growth in a decade. Several newer products ar", "date_published": "2026-08-10T22:36:57+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:1810cfe780396af526d2dcbea72cac0b1203480f9a77542bd5f76951829891ea", "url": "https://finance.yahoo.com/markets/stocks/articles/medtronic-mdt-increases-despite-market-214502376.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/medtronic-mdt-increases-despite-market-214502376.html", "title": "Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know", "content_text": "In the latest close session, Medtronic (MDT) was up +2.58% at $89.41. The stock outperformed the S&P 500, which registered a daily loss of 0.06%. Elsewhere, the Dow lost 0.11%, while the tech-heavy Nasdaq lost 0.32%. The medical device company's stock has climbed by 3.92% in the past month, exceeding the Medical sector's loss of 0.38% and the S&P 500's gain of 3.42%. The upcoming earnings release of Medtronic will be of great interest to investors. The company's earnings report is expected on September 1, 2026. On that day, Medtronic is projected to report earnings of $1.39 per share, which wo", "date_published": "2026-08-10T21:45:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:d3ab2b7502c0abaac5cde1db78f3d61c3eea5a4004021eb3d7b5a05c0c8bffc5", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-abbott-laboratories-204959195.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-abbott-laboratories-204959195.html", "title": "Johnson & Johnson vs Abbott Laboratories: Which Healthcare Giant Offers the More Compelling Growth Story After Earnings?", "content_text": "Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 \u2060billion, above analysts' average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its guidance and stated that it is on track to meet its 2026 goal of over $100 billion in annual revenue for the first time in its 140-year history. Abbott Laboratories (NYSE:ABT) also beat its quarterly estimates in its fiscal Q2 2026 results while also raising its annual profit forecast, with strong demand for its cancer diagnostics business and medical devices easing procedure-volume concerns. Sales for the quarter rose 13% on a reported basis and 4.8% on a comparable basis. So which healthcare giant offers the more compelling investment case for investors? Let's dive into it.Citi Believes Abbott (ABT) Shares are Undervalued Relative to Business Segments An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. Both healthcare giants beat quarterly estimates and raised their outlooks, suggesting continued resilience across their businesses. The key question for investors is whether Johnson & Johnson's (NYSE:JNJ) pharmaceutical growth story or Abbott Laboratories' (NYSE:ABT) expanding diagnostics and medical devices businesses offer the more compelling investment case going forward. Bull Case Johnson & Johnson's (NYSE:JNJ) pharmaceutical unit was an optimistic factor, as it helped increase total sales, generating $16.38 billion in quarterly sales and exceeding analysts' estimate of $16.1 billion. The healthcare giant now expects its annual sales to be around $101.1 billion at the midpoint, \u200bcompared with $100.8 billion \u2060previously. In another optimistic feat, it raised its adjusted earnings per share forecast to $11.68 at the midpoint, from a previous $11.55 per share. Revenue from Johnson & Johnson's (NYSE:JNJ) Stelara, which treats psoriasis, Crohn's disease, and \u200bother autoimmune conditions, dropped over 55% in the quarter to $740 million due to patent loss. However, the company's cancer and newer immunology drugs can be seen countering this loss, as sales of Tremfya, its psoriasis and inflammatory bowel disease drug, rose 72.5% to $2 billion, considerably exceeding the estimate of $1.74 billion. The most encouraging sign for investors thus may be Johnson & Johnson's (NYSE:JNJ) ability to absorb a significant patent-related decline in Stelara sales while still raising its full-year outlook. Strong performance from newer drugs such as Tremfya suggests the company's pipeline is successfully offsetting losses from older products. Story Continues On the other hand, Abbott Laboratories (NYSE:ABT) reported GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31, which excludes specified items, and reaffirmed its full-year 2026 comparable sales growth guidance of 6.5% to 7.5%, suggesting confidence in its operations. The company also raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to the previous range of $5.38 to $5.58. Abbott Laboratories (NYSE:ABT) diagnostics segment rose 42% to $3.09 billion in fiscal Q2, surpassing the estimate \u200bof $3.02 billion, emerging as one of the company's strongest performers during the quarter. This was driven by strong adoption in electrophysiology, diabetes care (such as CGM systems), and expanding cancer screening diagnostics. William Blair stated that the company's cancer diagnostics results should improve sentiment around the Exact Sciences \u200bacquisition, with growth in medical devices helping offset concerns surrounding hospital procedure volumes. Bear Case Johnson & Johnson's (NYSE:JNJ) MedTech segment was comparatively less impressive during the quarter, with sales slightly missing expectations. Management attributed some of the weakness to temporary headwinds, including inventory-related pressures in China t", "date_published": "2026-08-10T20:49:59+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABTT34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABTT34", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/54923738-62b8-4347-824e-abcfed853bbd/"}]}}, {"id": "source:d010ce60e0526c4316a61eeda2801e4969c0e0ffa92f85fbf34fe5b5ce5e3794", "url": "https://finance.yahoo.com/healthcare/articles/orchestra-biomed-reports-second-quarter-201200454.html", "external_url": "https://finance.yahoo.com/healthcare/articles/orchestra-biomed-reports-second-quarter-201200454.html", "title": "Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates", "content_text": "Orchestra BioMed Holdings, Inc. The BACKBEAT global pivotal trial (\"BACKBEAT Trial\"), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met. Virtue pivotal trial is advancing with further site activations and patient enrollments. $110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand. Company to host R&D Day on November", "date_published": "2026-08-10T20:12:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:7703f3386bdf9c30a1da14a667b6a0c799897c5eec25c59526fc361155dd0b1c", "url": "https://finance.yahoo.com/markets/stocks/articles/boston-scientific-ceo-mahoney-buys-174601248.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/boston-scientific-ceo-mahoney-buys-174601248.html", "title": "Boston Scientific CEO Mahoney Buys More Than 200k Shares for $10 Million. What Does This Mean for Investors in 2026?", "content_text": "Michael F. Mahoney, Chairman, President & CEO of Boston Scientific Corporation (NYSE:BSX), purchased 186,240 shares of common stock at $48.34 per share on August 3, 2026. SEC Form 4 filing. Transaction summary Metric Value Transaction value $10.1 million Shares purchased 208,359 Post-transaction shares (total) 1,612,143 Post-transaction shares (directly held) 1,590,024 Post-transaction shares (indirectly held) 22,119 Post-transaction value $78.08 million Transaction value based on SEC Form 4 weighted average purchase price ($48.34); post-transaction value based on August 03, 2026 market close ", "date_published": "2026-08-10T17:46:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "B1SX34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "B1SX34", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/2490ca3f-bb1e-4ec5-a10a-2731c88f683b/"}]}}, {"id": "source:390765aa7addb2236810f0ab23ac9e6d6081e06b54be92e59ed0289d5d56666d", "url": "https://finance.yahoo.com/markets/stocks/articles/buy-hold-sell-abt-stock-144300730.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/buy-hold-sell-abt-stock-144300730.html", "title": "Should You Buy, Hold or Sell ABT Stock Amid Medical Devices Boom?", "content_text": "Abbott Laboratories' ABT Medical Devices remains its largest segment and continues to benefit from a strong pipeline of new product launches and growing adoption across cardiovascular care and diabetes management. The segment is well positioned to capitalize on the expanding global medical devices market. According to Fortune Business Insights, the global medical devices market was valued at $572.31 billion in 2025 and is projected to increase from $604.99 billion in 2026 to $1.03 trillion by 2034, reflecting a CAGR of 6.9% over the forecasted period. Given this favorable industry backdrop, Abbott's Medical Devices business maintained solid momentum in the second quarter of 2026, with sales increasing 8.4% on a comparable basis. Electrophysiology sales advanced 13.4%, while Rhythm Management, Heart Failure and Diabetes Care each delivered high-single-digit comparable growth. Notably, continuous glucose monitoring sales exceeded $2 billion, supported by the scale of Abbott's FreeStyle Libre franchise and its expanding adoption. Despite these encouraging growth trends, the broader Medical Devices sector continues to face macroeconomic headwinds, including policy uncertainty, persistent cost inflation and tariff-related pressures. These factors could weigh on operating costs and investor sentiment across the industry. Abbott shares have lost approximately 17.9% over the past year compared with a 23.9% decline for the broader Medical Products industry. During the same period, shares of key peers Boston Scientific BSX and GE HealthCare Technologies GEHC have declined 52% and 1.7%, respectively.Zacks Investment Research Image Source: Zacks Investment Research Major Tailwinds for ABT Stock EPD Momentum Across Emerging Markets: Abbott's Established Pharmaceuticals Division (\"EPD\") remains a steady contributor, supported by branded generics positions in faster-growing geographies. In the second quarter of 2026, EPD sales increased 8.4% on a reported basis and 8.7% on a comparable basis. Key emerging markets grew 10.7% on a comparable basis, led by double-digit growth in several countries across Latin America and Asia Pacific. The company is also expanding its biosimilar pipeline, which should deepen the portfolio in key markets. It expects EPD to sustain high-single-digit sales growth over time, supported by broad geographic demand, brand equity and disciplined commercial execution. Innovation-Led Reset in Nutrition: Abbott is working through a transition in Nutrition that is intended to restore a healthier balance between price and volume over time. In the second quarter of 2026, Nutrition sales increased $127 million sequentially as both Pediatric and Adult Nutrition improved. International Pediatric Nutrition returned to growth, rising 6.4% on a comparable basis, while recent Special Supplemental Nutrition Program for Women, Infants, and Children (\"WIC\") contract wins lifted Abbott to the leading position in both WIC and non-WIC channels. Story Continues In Adult Nutrition, U.S. retail consumption of Ensure increased at a double-digit rate from 2025-end levels, and international sales approached prior-year levels. New Ensure products with higher protein, lower sugar and refreshed packaging are also contributing. The company expects pricing actions, new products and commercial execution to support continued improvement in the second half of 2026. Estimates for ABT Heading North The Zacks Consensus Estimate for Abbott's 2026 sales and EPS implies a year-over-year improvement of 13.5% and 9.2%, respectively. The bottom-line estimates have shown upward movement in the past 30 days.Zacks Investment Research Image Source: Zacks Investment Research ABT's Downsides China Policy Risk Persists: China remains a source of uncertainty, particularly within Core Laboratory Diagnostics where volume-based procurement (VBP) has affected pricing and sales. Abbott mentioned that the China business had declined around 30% for at least five quarters befo", "date_published": "2026-08-10T14:43:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABTT34", "B1SX34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABTT34", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/54923738-62b8-4347-824e-abcfed853bbd/"}, {"symbol": "B1SX34", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/2490ca3f-bb1e-4ec5-a10a-2731c88f683b/"}]}}, {"id": "source:927f9ccad8a76401c0a14360109ddd557d24db34a3e730f18f16ee3d81dbc74b", "url": "https://finance.yahoo.com/healthcare/articles/isrg-trades-premium-p-e-144200115.html", "external_url": "https://finance.yahoo.com/healthcare/articles/isrg-trades-premium-p-e-144200115.html", "title": "ISRG Trades at a Premium P/E: Buy, Sell or Hold the Stock Now?", "content_text": "Intuitive Surgical ISRG currently trades at a forward 12-month P/E ratio of 33.02X, above the Medical - Instruments industry's 26.53X, underscoring a valuation premium that investors must weigh against the company's growth prospects. The stock carries a Value Score of D, suggesting that shares are not particularly inexpensive despite the compression in its valuation multiple. Second-quarter 2026 results nevertheless provided a solid operating baseline. Revenues increased 19% year over year to $2.89 billion, while adjusted earnings per share (EPS) rose 28% to $2.80. Total procedures increased 1", "date_published": "2026-08-10T14:42:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:c2cae5d842d00a04b75cba6303708340781f4106ae510a70c537c7440b2dcae8", "url": "https://finance.yahoo.com/markets/stocks/articles/said-4-dividend-aristocrats-could-134539654.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/said-4-dividend-aristocrats-could-134539654.html", "title": "We Said These 4 Dividend Aristocrats Could Soar. Here\u2019s How They Did, Plus 3 New Picks.", "content_text": "Quick Read ABBV surged 47% and BDX gained 26% over the past year, both decisively beating the market as their overlooked dividend growth drove outsized returns. All four original picks kept raising dividends regardless of price, with PG marking its 70th consecutive year of increases and BF-A its 82nd. ALB, MDT, and SWK offer cyclical, defensive, and industrial dividend plays, each with dramatically improved free cash flow coverage heading into fiscal 2027. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to ", "date_published": "2026-08-10T13:45:39+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:6a7f281ce2bb1823c3712f316b0761ba9ab889f185b0fe61e52d14c509cd0ab6", "url": "https://finance.yahoo.com/markets/stocks/articles/varex-imaging-vrex-q3-earnings-121505093.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/varex-imaging-vrex-q3-earnings-121505093.html", "title": "VAREX IMAGING (VREX) Q3 Earnings Beat Estimates", "content_text": "VAREX IMAGING (VREX) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +40.91%. A quarter ago, it was expected that this company would post earnings of $0.22 per share when it actually produced earnings of $0.21, delivering a surprise of -4.55%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. VAREX IMAGING, which belongs to the ", "date_published": "2026-08-10T12:15:05+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:455f96e15db4bb8b0af01b95c9642b11502fa4455a603549f01df4629a717c6c", "url": "https://finance.yahoo.com/healthcare/articles/medtronic-mdt-becoming-turnaround-story-234359487.html", "external_url": "https://finance.yahoo.com/healthcare/articles/medtronic-mdt-becoming-turnaround-story-234359487.html", "title": "Is Medtronic (MDT) Becoming a Turnaround Story?", "content_text": "UBS upgraded Medtronic (NYSE:MDT) to a Buy from Neutral today, telling investors in a research note that a \"turnaround\" is underway at the company. The upgrade raises an important question for investors: Is Medtronic finally returning to sustainable growth after years of underperformance, or is it too early to call the turnaround complete?Truist Maintains Hold on Medtronic (MDT), Seeks Stronger EPS Growth Bull case One of the most prominent factors supporting Medtronic's (NYSE:MDT) turnaround story is the company's reporting of its highest annual revenue growth in 10 years in its fiscal Q4 and", "date_published": "2026-08-09T23:43:59+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:cfa2e9eeef0f04003ff3ff3d17190b682d47e0feabacf8398b58a2ff1baa3870", "url": "https://www.nasdaq.com/articles/medtronic-vs-intuitive-surgical-which-medtech-stock-better-buy-right-now", "external_url": "https://www.nasdaq.com/articles/medtronic-vs-intuitive-surgical-which-medtech-stock-better-buy-right-now", "title": "Medtronic vs. Intuitive Surgical: Which MedTech Stock Is the Better Buy Right Now?", "content_text": "Key Points Medtronic has launched new devices that will help further improve its financial results. Intuitive Surgical's latest da Vinci system could expand its addressable market. Each stock will appeal to investors with different priorities. 10 stocks we like better than Medtronic \u203a Medtronic(NYSE: MDT) and Intuitive Surgical(NASDAQ: ISRG), two medical device leaders, haven't performed well this year. While weakness in the broader healthcare sector hasn't helped, they have both encountered company-specific issues that have contributed to their lagging the market. The good news is that there ", "date_published": "2026-08-08T21:20:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:0228fda7a01299989d2cdb3dc45402850ea86f8309b6e3713d2645b01b96fb53", "url": "https://www.nasdaq.com/articles/competition-heating-heres-why-intuitive-surgical-might-still-be-smartest-bet-medtech", "external_url": "https://www.nasdaq.com/articles/competition-heating-heres-why-intuitive-surgical-might-still-be-smartest-bet-medtech", "title": "Competition Is Heating Up, but Here's Why Intuitive Surgical Might Still Be the Smartest Bet in MedTech", "content_text": "Key Points Intuitive Surgical makes the da Vinci surgical robot, with 11,710 systems in use globally. Medical device competitors Medtronic and Johnson & Johnson are bringing out their own surgical robots. Intuitive Surgical's largest revenue source isn't the sale of new da Vinci systems.10 stocks we like better than Intuitive Surgical \u203a Intuitive Surgical(NASDAQ: ISRG) can be hard to own because the stock is prone to deep drawdowns. It is in a drawdown right now, with the stock down roughly 40% from its early 2025 high. Even after that drop, the price-to-earnings ratio remains lofty at 42x. Th", "date_published": "2026-08-08T16:35:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:053419f368676f2469ea023f4e0a3e1b2e945ed3c1994c5c34801aa4bc954f69", "url": "https://finance.yahoo.com/markets/stocks/articles/abbott-laboratories-abt-could-10-161147968.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/abbott-laboratories-abt-could-10-161147968.html", "title": "Abbott Laboratories (ABT) Could Be 10% Undervalued On Its $1.35b Buyback Update", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Abbott Laboratories buyback update Abbott Laboratories (ABT) has completed a share repurchase tranche that saw the company buy back 14,015,097 shares for about US$1.35b, including 11,599,094 shares between April and June 2026. See our latest analysis for Abbott Laboratories. Abbott Laboratories shares trade at US$107.81 and have gained 27.86% over the past 90 days, while the year-to-date share price return is down 13.19% and the 1-year total shareholder return is down 17.86%. This points to improving short-term momentum after a weaker period. Recent drivers include the completed US$1.35b buyback program and the April acquisition of Exact Sciences, alongside lower 2026 guidance linked to earnings dilution from that deal. If you are looking beyond Abbott Laboratories for other healthcare ideas, this could be a good moment to scan for companies at the crossroads of medicine and AI using our 43 healthcare AI stocks Abbott Laboratories has rebounded sharply in the last quarter after a weaker year and a US$23b acquisition that diluted guidance. Is this just a catch up move, or does the current valuation leave meaningful upside ahead? Most Popular Narrative: 9.5% Undervalued The most followed narrative currently places Abbott Laboratories' fair value at $119.13, which sits above the last close at $107.81 and frames the recent rebound in a valuation context. The expansion of healthcare access and rising middle class in key emerging markets (such as India, China, Latin America, and the Middle East) is fueling robust growth in branded generics and biosimilars, highlighted by Abbott's record sales in these regions and imminent biosimilar launches; this trend is described as a potential driver of ongoing double-digit top-line growth and greater geographic revenue diversification. Read the complete narrative. Want to understand why this narrative still justifies a premium multiple on future earnings? The key is how revenue growth, margin expansion and a richer product mix interact over the next few years. Result: Fair Value of $119.13 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Abbott Laboratories still faces key risks, including pricing pressure in diagnostics and glucose monitoring, as well as potential earnings drag from tariffs and foreign exchange moves. Find out about the key risks to this Abbott Laboratories narrative. Story Continues Next Steps The mix of risks and rewards around Abbott Laboratories is clear, so it makes sense to review the data yourself and decide quickly where you stand. To see both sides in one place, start with these 3 key rewards and 2 important warning signs Looking for more Abbott Laboratories investment ideas? If you follow Abbott Laboratories, do not stop here. Use this moment to broaden your watchlist and compare other opportunities that might fit your goals even better. Target strong value potential by scanning companies that combine quality fundamentals with attractive pricing using our 51 high quality undervalued stocks. Boost your income focus by reviewing businesses with higher yields and resilient payout histories via our 8 dividend fortresses. Protect your downside by assessing companies with stronger balance sheets and cleaner financial profiles through our solid balance sheet and fundamentals stocks screener (49 results). This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest pric", "date_published": "2026-08-08T16:11:47+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABTT34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABTT34", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/54923738-62b8-4347-824e-abcfed853bbd/"}]}}, {"id": "source:ef97591fe7287717984e55a5dbfd4afdc7056c911aa271ab0319d5876ea6e60b", "url": "https://finance.yahoo.com/healthcare/articles/robotic-surgery-leader-intuitive-surgical-110549493.html", "external_url": "https://finance.yahoo.com/healthcare/articles/robotic-surgery-leader-intuitive-surgical-110549493.html", "title": "The Robotic Surgery Leader: Intuitive Surgical Slides Further But One Wall Street Bull Pegs Returns at 85%", "content_text": "Quick Read ISRG dropped 34% on a slower procedure growth guide, yet Q2 EPS of $2.80 crushed the $2.50 consensus for a fifth straight quarterly beat. ISRG trades 28% below Wall Street consensus while peers MDT and SYK fell less than 10% YTD, suggesting the market overcorrected on the category leader. Bernstein's $685 target implies 83% upside with the bull case hinging on the da Vinci 5 upgrade cycle mirroring the prior seven-year Xi ramp. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Intuitive Surgical didn't make the cut. Grab the names FREE today. Intui", "date_published": "2026-08-08T11:05:49+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:698d2d60f12e11184bf21389045f19e03864bcf105bc52b5c5c13033f44938e1", "url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE9MMzFuWk9RNmZnMldYQ2VYenpld3hjUEdlUC1zbDlJaWRJTkhLLVBrSVNkT2tEWlhmRUNTTWxYVFBYclR0NGpJX2pVN0ZpdXd6TEtLc0V1NzlQUGctd2x2dWJzbGFmX3lVSkE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE9MMzFuWk9RNmZnMldYQ2VYenpld3hjUEdlUC1zbDlJaWRJTkhLLVBrSVNkT2tEWlhmRUNTTWxYVFBYclR0NGpJX2pVN0ZpdXd6TEtLc0V1NzlQUGctd2x2dWJzbGFmX3lVSkE?oc=5", "title": "Proje\u00e7\u00f5es de Resultados: Dexcom Inc (DXCM) \u2014 LPA e Crescimento de Receita", "content_text": "Proje\u00e7\u00f5es de Resultados: Dexcom Inc (DXCM) \u2014 LPA e Crescimento de Receita", "date_published": "2026-08-08T07:57:11+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "D1EX34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "D1EX34", "name": "DexCom, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b2c00c38-8c26-4d9c-a6aa-ac60da580f5e/"}]}}, {"id": "source:8a4a791cca70b4beebb809c5f2a1ed4b675fe78145cbd17af5a9f36e22a31096", "url": "https://finance.yahoo.com/healthcare/articles/medtronic-mdt-wins-expanded-ce-020910766.html", "external_url": "https://finance.yahoo.com/healthcare/articles/medtronic-mdt-wins-expanded-ce-020910766.html", "title": "Medtronic (MDT) Wins Expanded CE Mark For Affera System In Ventricular Arrhythmias", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Medtronic (NYSE:MDT) receives expanded CE Mark indication for its Affera Mapping and Ablation System and Sphere-9 Catheter for ventricular arrhythmia treatment. The Sphere-9 catheter also holds a Breakthrough Device Designation from the U.S. FDA, which highlights its potential clinical impact. This broader regulatory progress could influence Medtronic's position in cardiac arrhythmia care across international markets. As cardiac care technology evolves and Medtronic advances ", "date_published": "2026-08-08T02:09:10+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:1a7722a5ce946e9825b802ae190d0e0750e73ea1500c6bef62c381104b2545b8", "url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTE95d0ZkYUc4TXNwOFFtWnk1c2Ftb0hHd2JnTnhMMDRJUGpwazdVUVh5LUo0c1JMVUdFdVYxck9CdGpYZHZOYmpxUnkyMWdfOUd4U1ZHVEhZUndmMVpqSHJ4UGh3NA?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTE95d0ZkYUc4TXNwOFFtWnk1c2Ftb0hHd2JnTnhMMDRJUGpwazdVUVh5LUo0c1JMVUdFdVYxck9CdGpYZHZOYmpxUnkyMWdfOUd4U1ZHVEhZUndmMVpqSHJ4UGh3NA?oc=5", "title": "Not\u00edcias das A\u00e7\u00f5es da Medtronic PLC (MDT)", "content_text": "Not\u00edcias das A\u00e7\u00f5es da Medtronic PLC (MDT)", "date_published": "2026-08-07T21:19:32+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:0430c59c3e06fa7c605501d25add16896d0864a67a6c21fcdb18e4d186dc3014", "url": "https://finance.yahoo.com/healthcare/articles/boston-scientific-bsx-recalls-mean-190939502.html", "external_url": "https://finance.yahoo.com/healthcare/articles/boston-scientific-bsx-recalls-mean-190939502.html", "title": "What Do Boston Scientific (BSX) Recalls Mean For Device Safety And Clinical Use?", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Boston Scientific (NYSE: BSX) has initiated multiple product recalls covering cardiac ablation generators and vascular access sheaths due to labeling discrepancies and air embolism risks. The recalls affect a broad mix of devices used in cardiac and vascular procedures across several international markets. Regulators and hospitals are assessing the implications for device safety protocols, clinical workflows, and future use of the impacted products. Produc", "date_published": "2026-08-07T19:09:39+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "B1SX34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "B1SX34", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/2490ca3f-bb1e-4ec5-a10a-2731c88f683b/"}]}}, {"id": "source:71b24acfa7415147633d013960cd37427f9a8b3dfdb4340435842e559f5708f3", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxQTUZXY1IwSnBueGVvN0lMaFJsdDZ1cHFlelJBbThESnFXZDBYSVZxQy1GZ2FKc1Q4UDhOMmVRNzFmd0tqWWItSjJubm1ydE4tUEYxRTFEb3ZSUWo2Wmh6T2ZEcmpDSVRvZHRvY3p4SW8yZFlPN0NSbFBPSllfWlhWM3ZzSmE3dGxuV1B5bEYydmo5ZWJlRDlzUGdGdllvVzZBM2hxMHhKMDQ5b1pNbWRuQmRpTnJld3RFNjNnMEtqWUZtZm85WmtrX21NZEdvNWFoWDM4bjVSc3ZSVzVTd3BUZ1hRWkZuTmtuR0F4R3l4QU8xSk0?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxQTUZXY1IwSnBueGVvN0lMaFJsdDZ1cHFlelJBbThESnFXZDBYSVZxQy1GZ2FKc1Q4UDhOMmVRNzFmd0tqWWItSjJubm1ydE4tUEYxRTFEb3ZSUWo2Wmh6T2ZEcmpDSVRvZHRvY3p4SW8yZFlPN0NSbFBPSllfWlhWM3ZzSmE3dGxuV1B5bEYydmo5ZWJlRDlzUGdGdllvVzZBM2hxMHhKMDQ5b1pNbWRuQmRpTnJld3RFNjNnMEtqWUZtZm85WmtrX21NZEdvNWFoWDM4bjVSc3ZSVzVTd3BUZ1hRWkZuTmtuR0F4R3l4QU8xSk0?oc=5", "title": "Daniel Lippis, vice-presidente corporativo da Edwards Lifesciences, vende a\u00e7\u00f5es no valor de US$ 21.183 - Investing.com Brasil", "content_text": "Daniel Lippis, vice-presidente corporativo da Edwards Lifesciences, vende a\u00e7\u00f5es no valor de US$ 21.183 - Investing.com Brasil", "date_published": "2025-04-08T07:00:00+00:00", "authors": [{"name": "Finan\u00e7as, C\u00e2mbio e Investimentos"}], "tags": ["Market update", "E1WL34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "E1WL34", "name": "Edwards Lifesciences Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/e03db612-2d5a-4b57-b1aa-2c90a6753007/"}]}}, {"id": "source:8fce52beca25f9d2e4323d3e9893bf1e8292b3541eb0493f0e77216ab272733a", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE5icmI0RkU1U3Z2VElBZ3JTSkNFRGZhYU82S3lKRW9NLVk4WDkxaURjWVRPb0VzYlBiZGx4QlEtdUJ4cVk3MEVWelRPQUpkbXp3Tnc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE5icmI0RkU1U3Z2VElBZ3JTSkNFRGZhYU82S3lKRW9NLVk4WDkxaURjWVRPb0VzYlBiZGx4QlEtdUJ4cVk3MEVWelRPQUpkbXp3Tnc?oc=5", "title": "BDR DexCom - D1EX34 - Resultados, Dividendos, Cota\u00e7\u00e3o e Indicadores", "content_text": "BDR DexCom - D1EX34 - Resultados, Dividendos, Cota\u00e7\u00e3o e Indicadores", "date_published": "2021-05-05T02:35:29+00:00", "authors": [{"name": "Investidor10"}], "tags": ["Market update", "D1EX34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "D1EX34", "name": "DexCom, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b2c00c38-8c26-4d9c-a6aa-ac60da580f5e/"}]}}]}